Previous Close | 10.20 |
Open | 10.16 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 10.16 - 10.16 |
52 Week Range | 5.54 - 10.64 |
Volume | 216 |
Avg. Volume | 2,062 |
Market Cap | 4.659B |
Beta (5Y Monthly) | 0.82 |
PE Ratio (TTM) | 14.70 |
EPS (TTM) | 0.69 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Oct 04, 2018 |
1y Target Est | N/A |
Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday. Stephen Saad told Reuters in an interview that the technology transfer from J&J has "gone very well, and we are now committing (to) commercial supply in our financial year", which ends June 30. Aspen's production timeline for the vaccine is critical for South Africa as the country is relying heavily on J&J's doses to inoculate a significant portion of the 40 million people it is targeting to reach so-called herd immunity.
Aspen Pharmacare plans to start supplying Johnson & Johnson COVID-19 vaccine doses from its facility in South Africa before the end of June, its chief executive said on Friday. Stephen Saad told Reuters in an interview that the technology transfer from J&J has "gone very well and we are now committing commercial supply in our financial year." The company has committed 300 million COVID-19 vaccine doses, however the final amount that will be manufactured will depend on demand from J&J, he said.
Aspen Pharmacare could start production of Johnson & Johnson COVID-19 vaccines in South Africa by late March or early April if all approvals are in place, a senior company executive said. All the vaccines produced will be exported to J&J and will be a part of its global supply inventory, Stavros Nicolaou, Group Senior Executive, Strategic Trade at Aspen, added.